Characteristic | Number of patients |
---|---|
Total number of patients | 75 |
Age at diagnosis (years) | |
≤50 | 35 |
>50 | 40 |
Range | 29 to 77 |
Tumor size (cm) | |
<2.0 | 20 |
≥2.0 | 55 |
Number of positive lymph nodes | |
0 | 21 |
1–3 | 21 |
>3 | 33 |
Histological grade | |
1 | 12 |
2 | 43 |
3 | 20 |
HER2 | |
Negative | 63 |
Positive | 12 |
Adjuvant therapy | |
None | 5 |
Endocrine therapy | 32 |
Chemotherapy | 2 |
Combined | 36 |
Disease-free interval (months) | |
Mean ± standard deviation | 39.9 ± 26.4 |
Median | 38 |
Range | 1 to 123 |
First-line endocrine therapy | |
Tamoxifen | 56 |
Aromatase inhibitors | 11 |
LH-RH agonist | 3 |
LH-RH agonist + tamoxifen | 4 |
Fulvestrant | 1 |